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Introduction  
Antigen-specific immunotherapy (ASI) has long been hailed as a promising strategy 
to induce or restore immune tolerance in beta cells, the loss of which underlies the 
development of type 1 diabetes. The approach is based on the observation that, in 
preclinical models, repeated administration of an antigen over days or weeks leads 
to a state of immunological unresponsiveness. When the antigen used is a major 
target of the immune response in an autoimmune disease, the result is tolerance 
and disease prevention.  
 
In the type 1 diabetes space, there are several efforts under development to realise 
the potential benefits of ASI, including daily oral insulin, peptide antigen 
immunotherapy (e.g. proinsulin peptide) and GAD conjugated to alum [1-4]. GAD is 
well established as an important autoantigen in type 1 diabetes, and anti-GAD 
antibodies and GAD-reactive T cells are early features of the disease process. GAD-
alum is an ASI strategy designed to induce T helper (Th) 2 counter-regulation of the 
pathological Th1 autoimmune process that is thought to underlie beta cell 
destruction. Manipulation of such autoimmune networks, which may be finely 
balanced between health and disease, presents an important opportunity to learn 
about self-reactivity and how it may be influenced. In the current issue of 
Diabetologia, Tavira et al describe such an opening [5]. 
 
 
GAD-alum for the prevention of beta cell loss in type 1 diabetes 
The potential therapeutic effect of GAD-alum in preventing beta cell loss in 
individuals with a recent diagnosis of type 1 diabetes has been evaluated in several 
studies, from Phases I to Phase III. Whilst there is clear evidence that GAD-alum 
increases GAD autoantibody levels and induces GAD-specific Th2 responses, the 
clinical results have been somewhat equivocal [1, 6-8]. The pivotal study is a Phase III 
GAD-alum trial in individuals with new-onset type 1 diabetes, which failed to meet 
its primary efficacy endpoint of preserving C-peptide production [9]. However, 
important subgroup analyses of this study revealed that beneficial effects of GAD-
alum use were indeed observed in individuals from non-Nordic countries, but not in 
the Nordic participants who comprised nearly half of the study cohort. The study by 
Tavira et al [5] provides data to argue that this discrepant outcome is not a result of 
geographical differences but of different influenza protection strategies in the 
various countries participating in the clinical trial. 
 
Influenza vaccination and GAD-alum efficacy The Phase III trial protocol prohibited 
the use of routine infectious-disease vaccines around the study period (<1 month 
before and <2 months after the first dose of GAD-alum). This is not uncommon in 
immunotherapy trials and is used as a means to avoid unknown adverse interactions 
with ASI or, in the case of immunotherapies with suppressive properties, to avoid 
reduced vaccine efficacy. Vaccine exclusion can be challenging to police, not least 
because of guidelines that individuals with diabetes should be vigilant in maintaining 
active immunity through vaccination, including annual national programmes for 
influenza prevention. In the case of the GAD-alum Phase III study, recruitment 
coincided with an H1N1 influenza virus pandemic; hence, under these 
circumstances, influenza vaccination was permitted. The majority of Swedish and 
Finnish participants were vaccinated with Pandemrix, which was not in use in non-
Nordic countries. This prompted Tavira and colleagues to examine whether 
Pandemrix use could have impacted upon GAD-alum immunotherapy outcomes [5]. 
The authors chose to address this by examining the effects of influenza vaccination 
on outcome measures in relation to the timing of Pandemrix administration. 
Participants were divided according to whether influenza vaccination was given less 
than 5 months (<150 days) or 5–15 months before or after the first dose of GAD-
alum. Individuals with a longer period between influenza vaccination and GAD-alum 
administration had higher GAD autoantibody levels, higher GAD-induced Th2 
cytokines and reduced C-peptide decline compared with those who were vaccinated 
close to GAD-alum therapy (as summarised in Fig. 1). The authors conclude that if 
Pandemrix is given too soon before or after GAD-alum injection, it may interfere 
with the desired clinical and mechanistic effects of ASI. 
 
The impact of influenza vaccination on GAD-specific immune responses  
Alum was selected as an adjuvant for GAD in order to steer away from a Th1-
dominated, proinflammatory cellular autoimmune response towards a Th2 
response, which favours humoral immunity (antibody production) [10]. Tavira et al 
demonstrated that individuals who received the influenza vaccination within close 
proximity of GAD-alum treatment had increased secretion of GAD-induced 
proinflammatory cytokines, such as IFN-γ and TNF-α, compared with those who 
received the vaccine further from GAD-alum therapy [5]. One speculation is that the 
increase in proinflammatory cytokines  may have contributed to the accelerated C-
peptide loss in the participants vaccinated <5 months before or after GAD-alum 
treatment. Conversely, an IL-13 dominated GAD-induced profile was observed in 
individuals with a 5–15 month gap between GAD-alum treatment and influenza 
vaccination. This Th2 skewing represents the anticipated response to GAD-alum and 
may have contributed to C-peptide retention in this group. It is also possible that the 
enhanced GAD-specific Th2 response in these individuals may have accounted for 
the increased humoral GAD-specific immunity observed in these participants; 
importantly, this observation fits with a previous report of elevated GAD antibodies 
in individuals treated with GAD-alum in a Phase III study [11]. However, there are 
some caveats to the study by Tavira et al; for example, there are no placebo 
comparisons and, therefore, it remains unknown whether the group vaccinated with 
Pandemrix >5 months before or after GAD-alum  benefitted from GAD-alum as a 
therapeutic agent or merely avoided any non-specific adverse effects of Pandemrix 
on beta cell destruction pathways (see Fig. 2) that are more active in the period soon 
after diagnosis. 
 
Intriguingly, differences in the GAD-specific immune response and C-peptide in 
participants vaccinated with the H1N1 vaccine and GAD-alum <5 months or >5 
months apart were only observed in the individuals who received two doses but not 
four doses of GAD-alum. It is plausible that four doses of GAD-alum is sufficient to 
overcome any modulatory effects of Pandemrix that were observed in the two-dose 
group. The authors also noted that they had previously observed greater C-peptide 
retention in individuals who received two doses vs four doses of GAD-alum [12]. 
Furthermore, levels of H1N1 antibodies were significantly reduced in individuals 
vaccinated with Pandemrix close to receiving GAD-alum in the group receiving four 
doses of the influenza vaccine, implying that responses to both GAD and influenza 
were reduced as a result of the close proximity of the two interventions. 
 
Cellular mechanisms for GAD-alum/influenza vaccine interference 
This study raises the possibility that influenza vaccination interferes with ASI, a 
phenomenon that is both intriguing from a mechanistic standpoint and worrying 
from a clinical and drug development vantage. It is known that the co-administration 
of vaccines can result in immunological interference [13] and it will be of interest to 
understand how such interference mechanisms apply in the setting of ASI. 
Sequential administration of vaccines can result in the suppression of a response to 
one antigen at the expense of another or reduced responses to both antigens. Such 
effects depend on the relative amounts of antigens administered, the relative sites 
of vaccination and the time interval between antigen administration. For example, 
an impaired response to one antigen over another upon co-administration of 
vaccines may arise as a result of competition between multiple antigen responses for 
limited resources within the lymph nodes, such as access to antigen, chemokines, 
activation signals, follicular dendritic cells and follicular Th cells, thereby affecting 
the level of T cell help, B cell activation and antibody production directed towards a 
given antigen. Alternatively, co-administered vaccines may change the balance of Th 
cell subsets, since different antigens may induce mutually antagonistic Th1 or Th2 
cytokine responses, or induce regulatory T cell mechanisms that could inhibit the 
immune response to one of the antigens administered. 
 
Tavira and colleagues speculate that the interference between influenza vaccination 
and GAD-alum administration observed in this particular setting could be 
attributable to the potent immunomodulatory effects of the adjuvant used in 
Pandemrix, AS03 [5]. AS03 has been shown to enhance the vaccine’s antigen-specific 
adaptive response by locally activating the innate immune system and by increasing 
antigen uptake and presentation in draining lymph nodes [14]. Since adjuvants act 
directly as immune stimulants, there is a possibility that they induce undesirable 
immune responses that could trigger the onset of immune-mediated disease in 
susceptible individuals. Indeed, following vaccination with Pandemrix during the 
2009 H1N1 pandemic, some European countries, including Sweden and the UK, 
reported the emergence in a small number of cases of narcolepsy, an immune-
mediated destruction of hypocretin-secreting neurons in the hypothalamus. 
Pandemrix elicits a transient, rapid and expansive activation of myeloid cells and 
effector cells, similar to the responses induced by other vaccines, including non-
adjuvanted influenza vaccines [15-20]. However, it also differs from other vaccines; 
the Human Immune Response Dynamics (HIRD) study in our laboratory showed that 
Pandemrix provokes an overt early-lymphoid response within 24 h of vaccination, 
with prominent upregulation of IFN-γ transcription, which has not been observed in 
most other virus vaccine studies [16]. Early-lymphoid- and myeloid-dominated 
responses were followed by a plasmablast-dominated response at day 7. Therefore, 
in participants vaccinated with Pandemrix soon before or after starting GAD-alum 
treatment, the notion that Pandemrix could affect GAD-associated immunity is, 
perhaps, not surprising, given that the outcome of auto-immunisation depends on 
the pre-existing immune background. For example, in the absence of inflammatory 
stimuli, an increased production of TGF-β and other immunomodulatory cytokines in 
response to Pandemrix may favour the generation of a tolerogenic response to 
administered autoantigen. On the other hand, a pre-existing pool of activated 
effector T cells and an aggressive proinflammatory response initiated by Pandemrix 
might instead aggravate autoimmunity and even accelerate autoimmune beta cell 
destruction. 
 
Intriguingly, the HIRD study also found that adverse events arising from Pandemrix 
vaccination were associated with an atypical pre-vaccination B lymphocyte 
phenotype, with an expanded transitional B lymphocyte pool (which is seen in 
autoimmunity) and higher levels of autoantibodies [16]. This observation might 
suggest that non-specific immune activation is enhanced in individuals with an 
autoimmune background, and a similar phenomenon might have contributed to the 
effects of Pandemrix in the GAD-alum study. 
 
 
Application of findings 
An important issue will be how this set of serendipitous observations from Tavira et 
al can and should be built upon. The first question is whether greater mechanistic 
insights can be gained in future studies, and the second is how it will impact upon 
the design of ASI trials. It is likely that new studies in man to address the many 
arising mechanistic questions are precluded by safety and feasibility issues and 
preclinical models may not be helpful in this setting. To further complicate matters, 
Pandemrix is no longer in use. Perhaps the best that can be achieved is to obtain 
robust vaccine record data in ASI studies and consider relevant sub-analyses in 
relation to study outcomes. What are the other implications for the design of ASI 
trials in type 1 diabetes? Perhaps it is reasonable for routine infectious-disease 
vaccines to be avoided for a period of 6 months before or after the ASI treatment 
period. However, in some settings (e.g. The Diabetes Prevention Trial of Type 1 
Diabetes [DPT-1], an oral insulin study; ClinicalTrial.gov registration no. 
NCT00004984) antigen administration is continuous over months/years and 
withholding vaccines is neither practical nor desirable. In addition, it is probable that 
natural exposures to infectious agents could have adverse effects on ASI and these 
remain beyond easy control. The study by Tavira et al highlights the need to consider 
the immune background on which ASI is administered more generally and 
emphasises the yin and yang of immune responsiveness in seeking to balance 
aggression and regulation in the face of complex external stimuli. 
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Fig. 1 Outcome of two doses of GAD-alum immunotherapy differs according to 
whether the Pandemrix influenza vaccination is administered <150 days or >150 
days from first GAD-alum dose. GADA, GAD autoantibodies 
 Fig. 2 Mechanisms by which Pandemrix may interact with GAD-alum 
immunotherapy. In the absence of Pandemrix, GAD-alum induces a Th2 response 
that counterbalances and limits destructive Th1-mediated responses. Pandemrix 
vaccination close to GAD-alum administration may result in the following scenarios: 
(1) competition between GAD and influenza (flu) responses in the lymph node; (2) 
elevated IFN-γ levels resulting from the Pandemrix-induced myeloid and lymphoid 
response create a proinflammatory environment and may thus promote a GAD-
specific Th1 response; (3) Th1 cytokine-activated B cells may contribute to the 
proinflammatory cytokine milieu; (4) Th1 cytokines may drive beta cell death directly 
and via cytotoxic T cells. β, beta cell; B, B cell; CTL, cytotoxic T lymphocyte; DC, 
dendritic cell; Mφ, macrophage; PC, plasma cell; Treg, regulatory T cell 
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